Mink therapeutics announces clinical data of allogeneic inkt cells (agent-797) in solid tumor cancers at the aacr annual meeting

New york, april 18, 2023 (globe newswire) -- mink therapeutics (nasdaq: inkt), a clinical-stage biopharmaceutical company specializing in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer t (inkt) cell therapies to treat cancer and other immune-mediated diseases, presented data at the american association of cancer research (aacr) annual meeting, demonstrating the clinical benefit of allo-inkts, agent-797, alone and in combination with anti-pd-1 in patients with refractory non-small cell lung cancer (nsclc), testicular, and gastric cancers.
INKT Ratings Summary
INKT Quant Ranking